Comparison 7. Pimecrolimus 1.0% BID vs. triamcinolone acetonide 0.1% BID.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clear or almost clear eczema (IGA 0 or 1)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 1 week	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 3 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.3 6 months	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
1.4 12 months	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Mild or absent pruritus (pruritus score 0 or 1)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
2.1 12 months	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3 Withdrawals	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.1 For any reason	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 For lack of efficacy	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.3 For adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4.1 Any adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 Skin infections	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.3 Viral skin infections	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.4 Bacterial skin infections	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.5 Application site skin burning	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]